{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "1368",
  "slug": "heart-risk-missed-in-younger-adults",
  "edition": "2026-11-10T12",
  "url": "https://hangingcontext.com/stories/2026-11-10/heart-risk-missed-in-younger-adults/",
  "newsroom": "health-biotech",
  "beat": null,
  "newsroom_title": "Health & Biotech",
  "angle": "Lifetime risk finds younger patients 10-year scores miss, while heart failure drug use still depends on who treats you.",
  "headline": "Heart risk is visible earlier than the system acts on it",
  "dek": "A lifetime risk model validated in 13 million adults, a prescribing study from the Veterans Affairs system, and a 3,557-patient cardiorenal study all point the same way: the risk is visible earlier than the system acts on it.",
  "published_at": "2026-11-10T12:45:11Z",
  "labels": {
    "trust": "reported",
    "trust_text": "Reported · 3 Manifests",
    "newsroom": "Health & Biotech"
  },
  "source_count": 3,
  "publishers": [
    "medrxiv-cardiometabolic-medicine",
    "medrxiv-epidemiology-public-health"
  ],
  "sources": [
    "medrxiv-cardiometabolic-medicine",
    "medrxiv-epidemiology-public-health"
  ],
  "distinct_source_count": 2,
  "key_facts": [
    {
      "text": "In a preprint, QRISK4-Lifetime validated in 13 million adults achieved C-indices of 0.860 in women and 0.845 in men, and identified 8.1% of the total with high lifetime risk below the 10% 10-year risk threshold, 72.8% of whom were under 40.",
      "cites": [
        {
          "claim_ids": [
            "1794274529298542186",
            "1794274529300542187"
          ],
          "manifest_id": "1794274161898540950"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint from the Veterans Affairs system, cardiology visits were associated with the highest adjusted odds of ARNI use (OR 2.30) and SGLT2i use (OR 1.99) after heart failure hospitalization, and pharmacist visits were also independently associated with increased use.",
      "cites": [
        {
          "claim_ids": [
            "1794271251245526090",
            "1794271251248526091",
            "1794271251250526092"
          ],
          "manifest_id": "1794270986087525281"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, provider-level variation in ARNI and SGLT2i use after heart failure hospitalization is substantial and independent of site-level clustering.",
      "cites": [
        {
          "claim_ids": [
            "1794271251245526090"
          ],
          "manifest_id": "1794270986087525281"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, 4.5% of chronic kidney disease patients without baseline heart failure in the CRIC study developed progressive cardiorenal syndrome within 12 months, with higher albumin to creatinine ratio a strong predictor (HR 2.44).",
      "cites": [
        {
          "claim_ids": [
            "1794267235415482251",
            "1794267235418482252",
            "1794267235420482253"
          ],
          "manifest_id": "1794266967198480914"
        }
      ],
      "self_reported": true
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "Three studies, one gap",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794274529298542186"
              ],
              "manifest_id": "1794274161898540950"
            },
            {
              "claim_ids": [
                "1794271251245526090"
              ],
              "manifest_id": "1794270986087525281"
            },
            {
              "claim_ids": [
                "1794267235415482251"
              ],
              "manifest_id": "1794266967198480914"
            }
          ],
          "markdown": "Three medRxiv preprints look at heart and kidney disease from three angles, and they describe the same gap from different sides. One builds a lifetime cardiovascular risk model and finds younger patients that 10-year scores miss. One studies prescribing after heart failure hospitalization and finds that whether a patient gets guideline treatment depends heavily on which provider they see. And one tracks chronic kidney disease patients and finds a small but important group whose heart and kidneys fail together within a year. All three are preprints, so none of this is peer-reviewed yet. Read together, they say the risk is visible earlier than the system acts on it."
        }
      ]
    },
    {
      "heading": "A lifetime lens finds younger patients",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794274529298542186",
                "1794274529300542187",
                "1794274529301542188"
              ],
              "manifest_id": "1794274161898540950"
            }
          ],
          "markdown": "The risk model is QRISK4-Lifetime, which extends cardiovascular risk prediction to age 95. Validated across 13 million adults, it achieved C-indices of 0.860 in women and 0.845 in men, matching the performance of the established QRISK4 model at the 10-year horizon. The point of the lifetime lens is who it catches: the model identified a group making up 8.1% of the total with high lifetime risk who fell below the 10% 10-year risk threshold, and 72.8% of that group were under 40 years old. These are people a 10-year score would call low risk, in a decade of life when prevention has the longest runway. The preprint presents lifetime risk assessment as a complement to 10-year risk assessment in clinical prevention discussions, not a replacement: the two horizons answer different questions, and the lifetime view is the one that speaks to younger adults."
        }
      ]
    },
    {
      "heading": "Treatment depends on who you see",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794271251245526090",
                "1794271251248526091",
                "1794271251250526092"
              ],
              "manifest_id": "1794270986087525281"
            }
          ],
          "markdown": "The prescribing preprint shows what happens after the risk becomes an event. Studying heart failure patients in the Veterans Affairs system, it found provider-level variation in ARNI and SGLT2i use after heart failure hospitalization that was substantial and independent of site-level clustering: the variation lives with individual providers, not just with hospitals. A large proportion of patients remained untreated after hospitalization despite established guidelines. Cardiology visits were associated with the highest adjusted odds of ARNI use, at an odds ratio of 2.30, and SGLT2i use, at 1.99, compared with other specialties. Pharmacist visits were independently associated with increased use of both drugs, at odds ratios of 1.14 for ARNI and 1.15 for SGLT2i. The implication drawn in the preprint is that interventions should focus on individual provider behaviour, since that is where the variation sits."
        }
      ]
    },
    {
      "heading": "When heart and kidney fail together",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794267235415482251",
                "1794267235418482252",
                "1794267235420482253"
              ],
              "manifest_id": "1794266967198480914"
            }
          ],
          "markdown": "The third preprint, from the Chronic Renal Insufficiency Cohort study of 3,557 patients, looks at the patients for whom the gap closes fastest. It found that 4.5% of chronic kidney disease patients without baseline heart failure developed progressive cardiorenal syndrome, defined as heart failure and end-stage kidney disease within 12 months. Higher albumin to creatinine ratio was a strong predictor, with a hazard ratio of 2.44, and novel biomarkers including TNF-alpha and GDF-15 were associated with progressive cardiorenal syndrome. Risk factors varied by the sequence of events, with heart failure before end-stage kidney disease looking different from end-stage kidney disease before heart failure, suggesting distinct pathways rather than one shared decline. For clinicians, the value is stratification: a small group can be identified early, and the markers that identify them include both routine measures and newer biomarkers."
        }
      ]
    },
    {
      "heading": "What to watch",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794274529301542188"
              ],
              "manifest_id": "1794274161898540950"
            },
            {
              "claim_ids": [
                "1794271251245526090"
              ],
              "manifest_id": "1794270986087525281"
            },
            {
              "claim_ids": [
                "1794267235415482251"
              ],
              "manifest_id": "1794266967198480914"
            }
          ],
          "markdown": "The three preprints point at decisions that are already available to health systems, even before peer review settles the details. A lifetime risk view changes who gets a prevention conversation, and the QRISK4-Lifetime numbers say the newly visible group is mostly under 40. A prescribing gap that sits with individual providers rather than sites points at provider-level interventions, and the data say cardiology involvement and pharmacist visits are the levers that already correlate with treatment. A cardiorenal syndrome that arrives within 12 months for about one in twenty patients without baseline heart failure points at earlier monitoring for the highest-risk kidney patients. What remains unknown is whether acting on these signals changes outcomes: whether lifetime risk discussions lead to earlier treatment, whether provider-level interventions close the prescribing gap, and whether the cardiorenal biomarkers hold up outside the CRIC cohort. All three preprints need that follow-up before they become practice."
        }
      ]
    }
  ],
  "unresolved": [
    "Whether lifetime risk discussions lead to earlier prevention or better outcomes.",
    "Whether provider-level interventions close the ARNI and SGLT2i prescribing gap.",
    "Whether the cardiorenal risk markers hold up outside the CRIC cohort.",
    "No peer review yet for any of the three preprints."
  ],
  "decision_card": {
    "not_for": [
      "Anyone looking for clinical guidance or peer-reviewed results."
    ],
    "useful_for": [
      "Clinicians and health system planners working on cardiovascular prevention.",
      "Researchers studying prescribing variation and cardiorenal risk."
    ],
    "compare_against": [
      "10-year cardiovascular risk scores alone.",
      "Site-level prescribing audits that ignore individual providers."
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-11-10T12"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1794274161898540950",
    "1794270986087525281",
    "1794266967198480914"
  ],
  "manifests": [
    {
      "title": "Development and 10-year validation of QRISK4-Lifetime for cardiovascular risk prediction in 13 million adults",
      "source_url": "https://medrxiv.org/content/10.64898/2026.11.07.26367485v1.full",
      "manifest_id": "1794274161898540950",
      "source_name": "medrxiv-epidemiology-public-health",
      "published_date": "2026-11-09"
    },
    {
      "title": "Provider-Level and Specialty Variation in ARNI and SGLT2i Use After Heart Failure Hospitalization",
      "source_url": "https://medrxiv.org/content/10.64898/2026.11.06.26367478v1.full",
      "manifest_id": "1794270986087525281",
      "source_name": "medrxiv-cardiometabolic-medicine",
      "published_date": "2026-11-09"
    },
    {
      "title": "Risk Factors for Progressive Cardiorenal Syndrome Events in Patients with Chronic Kidney Disease: The CRIC Study",
      "source_url": "https://medrxiv.org/content/10.64898/2026.10.30.26366964v1.full",
      "manifest_id": "1794266967198480914",
      "source_name": "medrxiv-cardiometabolic-medicine",
      "published_date": "2026-11-09"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1794274161898540950",
      "1794270986087525281",
      "1794266967198480914"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect/start",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1794274161898540950",
      "all": "for id in 1794274161898540950 1794270986087525281 1794266967198480914; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-11-10/heart-risk-missed-in-younger-adults/",
    "json": "https://hangingcontext.com/stories/2026-11-10/heart-risk-missed-in-younger-adults/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-11-10/heart-risk-missed-in-younger-adults/index.md",
    "newsroom": "https://hangingcontext.com/n/health-biotech/",
    "edition": "https://hangingcontext.com/editions/2026-11-10T12/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-11-11/disease-maps-get-granular/",
      "headline": "Dengue, malaria and heat deaths are being mapped at a finer grain",
      "slug": "disease-maps-get-granular"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-11/blood-tests-close-in-on-brain-disease/",
      "headline": "A blood test that tells brain from spine injury joins a week of brain biomarkers",
      "slug": "blood-tests-close-in-on-brain-disease"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-10/resistance-leaves-a-pattern/",
      "headline": "Resistance is not random: four preprints map where it hides",
      "slug": "resistance-leaves-a-pattern"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-10/new-chemistry-against-resistant-bugs/",
      "headline": "New chemistry for tuberculosis, and a harder look at how resistance is measured",
      "slug": "new-chemistry-against-resistant-bugs"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Save what you follow as a Beacon",
    "text": "A Beacon is a saved query that your agent pulls with an explicit lookback window. Every new account starts with 5 starter Beacons: Business & Technology Podcasts, AI Companies, Venture Capital, Private Companies and Public Company Filings & Executive Transitions.",
    "cta": {
      "label": "See Beacons",
      "url": "https://synorb.com/connect/start"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-11-10/heart-risk-missed-in-younger-adults/"
  }
}